A AGILENT TECHNOLOGIES, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 1090872 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY18.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR8.3%
Margins
Gross margin53.8%
Operating margin22.2%
Net margin19.5%
FCF margin17.2%
EBITDA margin25.9%
Returns
ROE21.0%
ROA11.0%
ROIC (approx.)16.0%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets47.3%
Debt / equity0.54x
Current ratio2.05x
Interest coverage15.46x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-1.3%
Payout ratio19.9%
Capex / revenue4.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.95B | $6.51B |
| Cost of revenue | $3.31B | $2.98B |
| Gross profit | $3.64B | $3.54B |
| R&D expense | $455.00M | $479.00M |
| SG&A expense | $1.71B | $1.57B |
| Operating income | $1.48B | $1.49B |
| Interest expense | $112.00M | $96.00M |
| Pretax income | $1.44B | $1.52B |
| Income tax | $132.00M | $232.00M |
| Net income | $1.30B | $1.29B |
| EBITDA | $1.77B | $1.75B |
| EPS (basic) | 4.59 | 4.44 |
| EPS (diluted) | 4.57 | 4.43 |
| Dividends declared per share | 0.99 | 0.94 |
| Weighted avg. shares (diluted) | 285.00M | 291.00M |
| Balance sheet | ||
| Cash & equivalents | $1.79B | $1.33B |
| Receivables | $1.49B | $1.32B |
| Inventory | $1.02B | $972.00M |
| Current assets | $4.59B | $3.96B |
| PP&E, net | $2.02B | $1.78B |
| Goodwill | $4.47B | $4.48B |
| Intangibles | $445.00M | $547.00M |
| Total assets | $12.73B | $11.85B |
| Current liabilities | $2.35B | $1.90B |
| Short-term debt | $304.00M | $45.00M |
| Long-term debt | $3.05B | $3.35B |
| Total debt | $3.35B | $3.39B |
| Total liabilities | $5.99B | $5.95B |
| Shareholders' equity | $6.74B | $5.90B |
| Net debt | $1.56B | $2.06B |
| Shares outstanding | 283.05M | 285.19M |
| Cash flow statement | ||
| Operating cash flow | $1.56B | $1.75B |
| Capital expenditure | $407.00M | $378.00M |
| Free cash flow | $1.15B | $1.37B |
| Investing cash flow | -$394.00M | -$1.26B |
| Financing cash flow | -$715.00M | -$752.00M |
| Depreciation & amortization | $288.00M | $257.00M |
| Stock-based compensation | $128.00M | $129.00M |
| Dividends paid | $282.00M | $274.00M |
| Share buybacks | $425.00M | $1.15B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.